{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Selatinib_Ditosilate",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.",
    "fdaUniiCode": "6Q2E32HVE7",
    "identifier": "C111764",
    "preferredName": "Selatinib Ditosilate",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C2167"
    ],
    "synonyms": [
      "SELATINIB DITOSILATE",
      "Selatinib Ditosilate"
    ]
  }
}